What is Vericiguat?

Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator used in the management of chronic heart failure with reduced ejection fraction (HFrEF), particularly in patients who have recently experienced worsening heart failure events. It is marketed under the brand name Verquvo and is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.
Reference: Armstrong et al., NEJM 2020

What are the other popular names for Vericiguat?

Vericiguat is primarily known by its brand name Verquvo. In clinical and academic literature, it is also referred to by its generic name, vericiguat.
Reference: Drugs.com: Vericiguat Overview

What is the drug classification of Vericiguat?

Vericiguat is classified as an oral soluble guanylate cyclase (sGC) stimulator. It falls under the broader category of heart failure medications and is specifically designated for use as an adjunct therapy in patients with chronic HFrEF.
Reference: FDA Verquvo Prescribing Information

What is the mode of action of Vericiguat?

Vericiguat works by both sensitizing soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and directly stimulating sGC independent of NO. This dual mechanism leads to increased production of cyclic guanosine monophosphate (cGMP), which promotes vasodilation, reduces myocardial stress, and exerts anti‑remodeling effects on the heart. These actions collectively help reduce cardiac workload and improve cardiovascular outcomes in patients with HFrEF.
Reference: Armstrong et al., NEJM 2020

How is Vericiguat used?

Vericiguat is used as part of a comprehensive treatment plan for adult patients with chronic HFrEF who have had a recent episode of worsening heart failure (e.g., hospitalization or need for outpatient intravenous diuretics). It is prescribed in addition to standard heart failure therapy (such as beta‑blockers, ACE inhibitors, or ARBs) to further reduce the risk of adverse cardiovascular events.
Reference: PARADIGM-HF and VICTORIA Trials – NEJM

What is the recommended dosage and administration for Vericiguat?

Dosage: The recommended starting dose is 2.5 mg once daily, which is gradually titrated upward (typically to 5 mg, then 10 mg, and ultimately 15 mg once daily) as tolerated by the patient.
Administration: Vericiguat is taken orally in capsule form and may be taken with or without food. Consistent daily dosing is crucial for maintaining its therapeutic effect.
Reference: FDA Verquvo Prescribing Information

What prescribing information is important for Vericiguat?

Indications: Vericiguat is indicated for patients with chronic heart failure with reduced ejection fraction (HFrEF) who have recently experienced worsening heart failure events.
Contraindications: It is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy and should not be coadministered with nitrates or other potent vasodilators.
Monitoring: Patients should have regular assessments of blood pressure, renal function, electrolytes, and signs of infection.
Reference: FDA Verquvo Prescribing Information

What safety information, warnings, and cautions are associated with Vericiguat?

Common Side Effects: These include hypotension, dizziness, anemia, and gastrointestinal discomfort.
Warnings & Cautions:
- Hypotension: Vericiguat can cause a significant drop in blood pressure, particularly during dose titration.
- Infection Risk: Although not as immunosuppressive as some other agents, patients should be monitored for signs of infection.
- Drug Interactions:
  - Nitrates and PDE5 Inhibitors: Concomitant use is contraindicated due to the risk of profound hypotension.
  - Other Antihypertensives: Combined use may amplify blood pressure–lowering effects, requiring careful monitoring.
- Renal and Hepatic Impairment: Dose adjustments and frequent monitoring may be necessary in patients with impaired renal or hepatic function.
  Reference: Armstrong et al., NEJM 2020, FDA Verquvo Label

What additional drug interactions should be considered with Vericiguat?

Nitrates and Phosphodiesterase Type 5 Inhibitors (e.g., sildenafil): Their combined use with Vericiguat is contraindicated due to an increased risk of severe hypotension.
Other Antihypertensive Agents: Coadministration may result in additive hypotensive effects.
CYP450 Enzyme Modulators: Although Vericiguat is not predominantly metabolized by CYP enzymes, caution is advised when it is used with drugs that significantly alter blood pressure or fluid balance.
Reference: Clinical Pharmacology Reviews, ACR Guidelines

Where can I learn more about Vericiguat and its clinical evidence?

For further details on clinical studies, dosing strategies, and safety monitoring, refer to the following resources:

FDA Verquvo Prescribing Information
Armstrong et al., NEJM 2020 – VICTORIA Trial
PubMed for additional peer‑reviewed research on vericiguat in heart failure
American College of Cardiology Guidelines

Final Thoughts

Vericiguat (Verquvo) is an innovative, orally administered sGC stimulator that significantly improves outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) who have experienced recent worsening heart failure events. By enhancing cGMP production, vericiguat promotes vasodilation and reduces cardiac stress, contributing to a decrease in cardiovascular events. However, due to its potent blood pressure–lowering effects and potential drug interactions (especially with nitrates and other vasodilators), it must be used with caution and under strict medical supervision.
Disclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.